{
  "title": "CME: continuing medical education or commercial marketing efforts",
  "outline": [
    {
      "level": "H1",
      "text": "CME: Continuing Medical Education or Commercial Marketing Efforts?",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Adriane Fugh-Berman MD",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Director, PharmedOut",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Department of Physiology and Biophysics",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Georgetown University Medical Center",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Box 571460",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Washington DC 20057-1460",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Ajf29@georgetown.edu",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Disclosure: Dr. Fugh-Berman has been a paid expert witness on behalf of plaintiffs in",
      "page": 1
    },
    {
      "level": "H1",
      "text": "litigation regarding pharmaceutical marketing practices.",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Fugh­Berman, A",
      "page": 2
    },
    {
      "level": "H1",
      "text": "Continuing medical education (CME) is the pharmaceutical industry’s most",
      "page": 2
    },
    {
      "level": "H1",
      "text": "important marketing tool. The development of marketing messages for a drug starts",
      "page": 2
    },
    {
      "level": "H1",
      "text": "seven to ten years before a drug is submitted for FDA approval. Many of the marketing",
      "page": 2
    },
    {
      "level": "H1",
      "text": "messages that are developed for each product do not mention the drug at all. A ‘pre-",
      "page": 2
    },
    {
      "level": "H1",
      "text": "launch’ marketing message might emphasize the importance of a specific physiologic",
      "page": 2
    },
    {
      "level": "H1",
      "text": "process in order to set the stage for acceptance of a drug that affects that mechanism,",
      "page": 2
    },
    {
      "level": "H1",
      "text": "or might create an unnecessary diagnostic distinction in order to establish a niche for a",
      "page": 2
    },
    {
      "level": "H1",
      "text": "drug entering a crowded market.",
      "page": 2
    },
    {
      "level": "H1",
      "text": "Selling disease",
      "page": 2
    },
    {
      "level": "H1",
      "text": "“Proving the case for investing in CME,” states:“The most significant benefits for",
      "page": 2
    },
    {
      "level": "H1",
      "text": "industry may include creating disease-state awareness and disease state",
      "page": 2
    },
    {
      "level": "H1",
      "text": "significance.”i1 Another marketing article notes that:“CME activities are most valuable in",
      "page": 2
    },
    {
      "level": "H1",
      "text": "introducing products early in their life cycles or for promoting mature brands with new",
      "page": 2
    },
    {
      "level": "H1",
      "text": "indications and new clinical data.”2",
      "page": 2
    },
    {
      "level": "H1",
      "text": "conditions in order to prepare, or expand, a market.3 Manipulating physicians’",
      "page": 2
    },
    {
      "level": "H1",
      "text": "understanding of the prevalence or severity of medical conditions can lead to",
      "page": 2
    },
    {
      "level": "H1",
      "text": "overtreatment, and expose patients to the adverse effects of drugs without significant",
      "page": 2
    },
    {
      "level": "H1",
      "text": "benefit.",
      "page": 2
    },
    {
      "level": "H1",
      "text": "and tests are never advertisements for a specific therapy because physicians will reject",
      "page": 2
    },
    {
      "level": "H1",
      "text": "speakers or articles that obviously favor a specific drug. One marketing message might",
      "page": 2
    },
    {
      "level": "H1",
      "text": "emphasize the risks of competing therapies; another the lack of evidence regarding an",
      "page": 2
    },
    {
      "level": "H1",
      "text": "over-the-counter remedy.",
      "page": 2
    },
    {
      "level": "H1",
      "text": "drug company to promote off-label use of a drug, CME is not considered promotion and",
      "page": 2
    },
    {
      "level": "H1",
      "text": "is not regulated by the FDA.  Physicians can say whatever they want, so are used as",
      "page": 2
    },
    {
      "level": "H1",
      "text": "mouthpieces for marketing messages that would be illegal coming from a company rep.",
      "page": 2
    },
    {
      "level": "H1",
      "text": "honestly, that they are expressing their independent opinions. However, they are",
      "page": 2
    },
    {
      "level": "H1",
      "text": "chosen because what they are saying aligns with a product’s marketing messages, and",
      "page": 2
    },
    {
      "level": "H1",
      "text": "are supported only as long",
      "page": 2
    },
    {
      "level": "H2",
      "text": "Raichle L. Proving the case for investing in CME. Medical Marketing & Media. Jun 1998;",
      "page": 2
    },
    {
      "level": "H1",
      "text": "33(6): 84.",
      "page": 2
    },
    {
      "level": "H1",
      "text": "Bottiglieri D.",
      "page": 2
    },
    {
      "level": "H3",
      "text": "008 5",
      "page": 2
    },
    {
      "level": "H1",
      "text": "Fugh-Berman A, Melnick D. Off-Label Promotion, On-Target Sales. PLoS Medicine 2",
      "page": 2
    },
    {
      "level": "H3",
      "text": "(10): e210 http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed",
      "page": 2
    },
    {
      "level": "H1",
      "text": "4 Fugh‐Berman A. Key opinion leaders: Thus are our medical meetings monitored. BMJ",
      "page": 2
    },
    {
      "level": "H1",
      "text": "2008;337:a789 http://www.bmj.com/cgi/content/full/337",
      "page": 2
    },
    {
      "level": "H1",
      "text": "/jul15_1/a789",
      "page": 2
    },
    {
      "level": "H1",
      "text": "Fugh­Berman, A",
      "page": 3
    },
    {
      "level": "H2",
      "text": "product’s efficacy, concerns about its risks, or enthusiasm for a competing therapy will",
      "page": 3
    },
    {
      "level": "H1",
      "text": "be unceremoniously dropped from a company’s speaker’s bureau.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Vetting bias in CME modules",
      "page": 3
    },
    {
      "level": "H1",
      "text": "companies or academic medical centers to attempt to ferret out bias in CME modules,",
      "page": 3
    },
    {
      "level": "H1",
      "text": "because both depend on industry for survival. In 2007, about half of the $2.5 billion",
      "page": 3
    },
    {
      "level": "H1",
      "text": "spent on CME came from pharmaceutical manufacturers. Seventy-two percent of the",
      "page": 3
    },
    {
      "level": "H1",
      "text": "income from events sponsored by medical education companies is from firms that",
      "page": 3
    },
    {
      "level": "H1",
      "text": "manufacture FDA-regulated products. Academic medical centers are only a little better;",
      "page": 3
    },
    {
      "level": "H1",
      "text": "57% of CME income to medical schools comes from industry.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "for bias, such review focuses on the detection of obvious advertising, the use of brand",
      "page": 3
    },
    {
      "level": "H1",
      "text": "rather than generic names, of drugs, and adequate disclosure of conflict of interest. No",
      "page": 3
    },
    {
      "level": "H1",
      "text": "matter how vigilant they are, CME providers are not trained in recognizing marketing",
      "page": 3
    },
    {
      "level": "H1",
      "text": "messages and cannot adequately assess industry-funded materials for bias.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Adequate vetting of CME modules would require knowledge of every drug, biologic,",
      "page": 3
    },
    {
      "level": "H1",
      "text": "device, and diagnostic test that every company is marketing, developing, or considering.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "The task becomes even more daunting when mergers, acquisitions, co-marketing",
      "page": 3
    },
    {
      "level": "H1",
      "text": "agreements and collaborative marketing arrangements for example, among companies",
      "page": 3
    },
    {
      "level": "H1",
      "text": "selling drugs in the same class) are taken into account. Similarly, disclosures of",
      "page": 3
    },
    {
      "level": "H1",
      "text": "financial conflicts of interest are impossible to interpret without knowing every",
      "page": 3
    },
    {
      "level": "H1",
      "text": "company’s marketing plan for every drug on the market or in the pipeline.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "‘Unrestricted’ grants",
      "page": 3
    },
    {
      "level": "H1",
      "text": "solution. Although the new PhRMA Code of Ethics does not allow sponsors (companies",
      "page": 3
    },
    {
      "level": "H1",
      "text": "that fund the event) to suggest speakers, sponsors may indicate which topics they are",
      "page": 3
    },
    {
      "level": "H1",
      "text": "interested in funding. “Unrestricted” grants provided for grand rounds and lunch",
      "page": 3
    },
    {
      "level": "H1",
      "text": "conferences depend on a sense of obligation rather than a quid pro quo. When lists of",
      "page": 3
    },
    {
      "level": "H1",
      "text": "recommended speakers are supplied to organizers, it is unstated, but nonetheless",
      "page": 3
    },
    {
      "level": "H1",
      "text": "understood, that company-paid speakers will be included in the lecture series.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "paid by the sponsor. The desired messages about particular products or diseases may",
      "page": 3
    },
    {
      "level": "H1",
      "text": "be made clear. Organizers understand that sponsors or exhibitors may withdraw if they",
      "page": 3
    },
    {
      "level": "H1",
      "text": "don’t like the content. Not every speaker in a lecture series or conference is chosen by",
      "page": 3
    },
    {
      "level": "H1",
      "text": "industry. Pharmaceutical companies refer to presentations with marketing messages as",
      "page": 3
    },
    {
      "level": "H1",
      "text": "“message talks,” and sponsored CME programs usually include talks that are not",
      "page": 3
    },
    {
      "level": "H1",
      "text": "connected with the sponsor’s product. Although these camouflage talks may involve",
      "page": 3
    },
    {
      "level": "H1",
      "text": "independent speakers, organizers know that they must avoid inviting speakers who",
      "page": 3
    },
    {
      "level": "H1",
      "text": "might criticize a sponsor’s products or oppose a sponsor’s marketing messages3.",
      "page": 3
    },
    {
      "level": "H1",
      "text": "overtreated at a sponsored event. And rarely will they hear positive recommendations",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Fugh­Berman, A",
      "page": 4
    },
    {
      "level": "H2",
      "text": "for a competitor’s product, a generic product, or a non-pharmacologic therapy at a",
      "page": 4
    },
    {
      "level": "H1",
      "text": "sponsored program.",
      "page": 4
    },
    {
      "level": "H2",
      "text": "ACCME",
      "page": 4
    },
    {
      "level": "H1",
      "text": "of interest are both weak and ignored. A 2007 annual report by the ACCME, however,",
      "page": 4
    },
    {
      "level": "H1",
      "text": "showed that 29% of providers failed to comply with Standard 2, which requires that any",
      "page": 4
    },
    {
      "level": "H1",
      "text": "individuals that control content of a CME activity disclose and resolve conflicts of",
      "page": 4
    },
    {
      "level": "H1",
      "text": "interest.6 27% of the providers did not comply with Standard 3, which includes",
      "page": 4
    },
    {
      "level": "H1",
      "text": "guidelines to prevent those with commercial interest from dictating the content of a CME",
      "page": 4
    },
    {
      "level": "H1",
      "text": "activity. And 36% of providers were noncompliant with Standard 6, which requires that",
      "page": 4
    },
    {
      "level": "H1",
      "text": "all commercial support and financial relationships of authors be disclosed to CME",
      "page": 4
    },
    {
      "level": "H1",
      "text": "participants before the activity. 6",
      "page": 4
    },
    {
      "level": "H1",
      "text": "members to report commercial bas. Although written complaints are accepted, the",
      "page": 4
    },
    {
      "level": "H1",
      "text": "process is burdensome The ACCME would not tell us whether or not any providers",
      "page": 4
    },
    {
      "level": "H1",
      "text": "have lost accreditation status due to commercial bias. Losing accreditation for any",
      "page": 4
    },
    {
      "level": "H1",
      "text": "reason is rare; according to the annual reports published by the ACCME only one",
      "page": 4
    },
    {
      "level": "H1",
      "text": "provider lost accreditation in 2005.",
      "page": 4
    },
    {
      "level": "H2",
      "text": "Conclusion",
      "page": 4
    },
    {
      "level": "H1",
      "text": "not do it. The large amount of commercial support poured into CME is in itself testimony",
      "page": 4
    },
    {
      "level": "H1",
      "text": "that industry believes supporting CME is cost-effective.  Industry influence on medical",
      "page": 4
    },
    {
      "level": "H1",
      "text": "discourse limits the discussion to the most profitable therapies, which may not be best",
      "page": 4
    },
    {
      "level": "H1",
      "text": "for patients. Industry-funded medical education is a contradiction in terms.",
      "page": 4
    },
    {
      "level": "H1",
      "text": "Acknowledgments: Alicia Bell MS, Margaret Infeld, Clare Murphy, Stephanie",
      "page": 4
    },
    {
      "level": "H1",
      "text": "Waterhouse, and Nicole Woodard provided background research.",
      "page": 4
    },
    {
      "level": "H2",
      "text": "About PharmedOut",
      "page": 4
    },
    {
      "level": "H3",
      "text": "and drug industry insider perspectives to educate prescribers about how covert marketing techniques",
      "page": 4
    },
    {
      "level": "H3",
      "text": "affect prescribing behavior. PharmedOut was launched through a grant from the Attorney General",
      "page": 4
    },
    {
      "level": "H3",
      "text": "Consumer and Prescriber Grant Program.",
      "page": 4
    },
    {
      "level": "H3",
      "text": "prescribing under the influence? Our unique approach draws on academic and marketing materials",
      "page": 4
    },
    {
      "level": "H2",
      "text": "5 ACCME. Essential Areas and Elements; 2008  Available via the Internet:",
      "page": 4
    },
    {
      "level": "H3",
      "text": "ttp://www.accme.org/dir_docs/doc_upload/f4ee5075-9574-4231-8876-",
      "page": 4
    },
    {
      "level": "H3",
      "text": "5e21723c0c82_uploaddocument.pdf. Accessed June 30, 2009",
      "page": 4
    },
    {
      "level": "H3",
      "text": "6 ACCME [Standards for Commercial Support; 2008 Available via the Internet:",
      "page": 4
    },
    {
      "level": "H3",
      "text": "ttp://www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-",
      "page": 4
    },
    {
      "level": "H3",
      "text": "80a1504e520c_uploaddocument.pdf. Accessed June 30, 2009.",
      "page": 4
    },
    {
      "level": "H1",
      "text": "Fugh­Berman, A",
      "page": 5
    },
    {
      "level": "H3",
      "text": "combined with original interviews with industry insiders to create novel articles, videos, and educational",
      "page": 5
    },
    {
      "level": "H3",
      "text": "materials. Our goal is to foster evidence-based, cost-effective prescribing and to decrease the adverse",
      "page": 5
    },
    {
      "level": "H3",
      "text": "public health effects of inappropriate pharmaceutical promotion.",
      "page": 5
    },
    {
      "level": "H3",
      "text": "funded, web-based continuing medical education (CME) courses – enough for any physician, nurse, or",
      "page": 5
    },
    {
      "level": "H3",
      "text": "pharmacist to complete annual continuing education requirements. Educational resources include our",
      "page": 5
    },
    {
      "level": "H3",
      "text": "slideshows, Drug Ad Bingo (a teaching exercise), Fast Facts on Generic Drugs (a factsheet for patients),",
      "page": 5
    },
    {
      "level": "H3",
      "text": "and seven original videos, featuring industry insiders. Our publications include Off-Label Promotion, On-",
      "page": 5
    },
    {
      "level": "H3",
      "text": "Target Sales,Following the Script: How Drug Reps Make Friends and Influence Doctors, Do New Drugs",
      "page": 5
    },
    {
      "level": "H3",
      "text": "Increase Life Expectancy?, Ethical Considerations of Publication Planning in the Pharmaceutical Industry,",
      "page": 5
    },
    {
      "level": "H3",
      "text": "Prescription Tracking and Public Health, Key Opinion Leaders: Thus Are Our Medical Meetings Managed,",
      "page": 5
    },
    {
      "level": "H3",
      "text": "and Smoke and Mirrors.",
      "page": 5
    },
    {
      "level": "H3",
      "text": "i Raichle L. Proving the case for investing in CME. Medical Marketing & Media. Jun 1998; 33(6): 84.",
      "page": 5
    }
  ]
}